Bioglutide (NA-931): What We Know So Far (and What We Don’t)

Bioglutide™ (NA-931) from Biomed Industries has generated buzz as a potential oral quadruple agonist that targets multiple metabolic receptors (GLP-1, GIP, glucagon, and IGF-1 pathways). Here’s a balanced, evidence-based overview.

Claimed mechanism & format

  • Mechanism (company claims): A quadruple agonist intended to enhance weight loss and glycemic control by engaging multiple receptors.
  • Oral candidate: The company positions NA-931 as an oral therapy under investigation.

Clinical status (2025)

  • Phase 2 presentations: Biomed reports Phase 2 data presented at the ADA 2025 meeting (details via company news releases).
  • Regulatory: NA-931 is investigational and not FDA-approved.

Lawsuits & safety context

High-profile litigation in 2024–2025 has targeted approved GLP-1 products (e.g., semaglutide brands) over alleged GI and other adverse events. These lawsuits do not pertain to Bioglutide, which remains in clinical development. As always, safety and efficacy must be established in robust, peer-reviewed trials before approval.

What to watch next

  • Peer-reviewed publication: Independent verification of Phase 2 data.
  • Long-term safety: Multi-receptor agonism may increase efficacy but could also broaden side-effect profiles—dose-finding is key.
  • Comparators: Head-to-head studies against weekly GLP-1 or dual agonists will clarify value.

FAQs

Is Bioglutide available?
No. It’s investigational.

Are there lawsuits about Bioglutide?
No publicly reported lawsuits specific to Bioglutide as of August 17, 2025. Ongoing litigation largely involves approved GLP-1 drugs (e.g., semaglutide brands).

Sources

Important: Company press releases are preliminary. Interpret efficacy/safety claims cautiously until peer-reviewed publications or regulatory filings provide complete data.

Disclaimer

 This content is intended for informational and educational purposes only and is not intended to promote or sell any product. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new supplement or research compound. The statements provided have not been evaluated by the FDA or Health Canada and are subject to change as scientific understanding evolves.

Back to blog